FDA Breakthrough Therapy designation: what it does and does not do

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Sources accessed 17 October 2026.

What the designation is

Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that treat a serious condition, where preliminary clinical evidence indicates the drug may show substantial improvement over available therapy on a clinically significant endpoint. Whether the improvement is substantial depends on the size and duration of the effect and how important the outcome is.^[1]

A clinically significant endpoint generally means an effect on irreversible morbidity or mortality, or on symptoms that represent serious consequences of the disease. FDA also accepts findings that suggest such an effect, such as an effect on a surrogate endpoint reasonably likely to predict benefit, a strong pharmacodynamic biomarker signal, or a clearly improved safety profile with similar efficacy.^[1]

What the company gets

• All Fast Track designation features.^[1]
• Intensive FDA guidance on an efficient development program, beginning as early as Phase 1.^[1]
• An organizational commitment involving FDA senior managers.^[1]

The sponsor requests the designation, ideally no later than the end-of-phase-2 meetings. FDA responds within 60 days of receiving the request. FDA may suggest that a sponsor apply if the data look promising.^[1]

What it means for patients

A Breakthrough Therapy designation is news about a drug's development, not a way to obtain it. Families sometimes read the headline and assume the drug can be ordered. It cannot be supplied commercially until FDA approves it.

Before approval, the options are a clinical trial or US expanded access, which needs the manufacturer's agreement and FDA authorization for the specific patient. For a patient abroad, the destination regulator must also agree.^{[2, 3]}

Reserve Meds coordinates access to FDA-approved medicines only. When a designated drug is approved, it can be requested from the Gulf through the usual routes.

After approval: reaching a patient in the Gulf

Why this matters in the Gulf: Saudi Arabia's SFDA runs reliance pathways that build on decisions by other regulators. Its performance target is 30 working days for the verification pathway, which needs approval and marketing by both the US FDA and the EMA, and 60 working days for the abridged pathway, which needs one of them. The manufacturer still has to apply; nothing happens automatically.^[4]

Until a medicine is registered locally, a patient in the Gulf usually reaches an FDA-approved medicine through a hospital request to the national regulator, such as the SFDA Special Access Program in Saudi Arabia or the procedure in NHRA Circular 41 of 2020 in Bahrain.^{[5, 6]}

How FDA's four expedited programs compare

• Fast Track: for drugs that treat serious conditions and fill an unmet need. It brings more frequent FDA meetings and written communication, possible rolling review of completed sections of the application, and eligibility for accelerated approval and priority review if criteria are met.^[7]
• Breakthrough Therapy: for drugs whose early clinical evidence suggests substantial improvement over available therapy. It includes all Fast Track features plus intensive guidance from Phase 1 and senior management involvement.^[1]
• Accelerated Approval: an approval based on a surrogate or intermediate endpoint reasonably likely to predict benefit, with confirmatory trials required.^[8]
• Priority Review: FDA's goal is to act on the application within 6 months, compared with 10 months under standard review. We give you a written timeline estimate for your case before you commit.^[9]

Only accelerated approval is an approval. The other three change how a drug is developed or reviewed; none of them makes a drug available before approval.

Questions to ask the treating specialist

• Is this drug approved by FDA yet, or only designated? Where can we read the US label?
• Is there a clinical trial my relative could join, and where are its sites?
• If there is no trial, would you ask the manufacturer about expanded access, and would our regulator allow the import?
• If the drug is approved, is it registered here, and if not, will the hospital request it for us?

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help families and treating doctors understand the route, prepare the documents the regulator or hospital asks for, arrange supply from the US once approval is in place, and keep everyone updated. We do not diagnose, prescribe or decide what a regulator approves.

We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.

Sources for these answers: ^{[1, 2]}

Related

• FDA accelerated approval
• US expanded access (compassionate use)
• All access pathways
• US expanded access (compassionate use)
• Named-patient access, explained
• Answers to common access questions

This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.